The multidrug resistance ( MDR1 ) gene product, P-glycoprotein (Pgp) 
INTRODUCTION
The lack of proper criteria defining multidrug resistance ( MDR1 ) or P-glycoprotein (Pgp) quantitation might explain the enormous variability in MDR1 gene expression in a number of studies (13, 19) . Since MDR1levels are often elevated in drug-selected cell lines, reliable quantification of low-level resistance has proven to be difficult and thus has escaped the realms of most studies. Reliable detection of low-level mRNA is very important, considering the prognostic relevance of MDR1in predicting the clinical outcome in hematological neoplasia (3, 5, 15) . In our view, the importance of a consensus between methodologies is as important as defining the threshold of expression that confers drug resistance. To establish the number of MDR1mRNA molecules required to mediate the MDR phenotype, consistency between detection techniques is vital in addressing these issues. Numerous studies examining MDR1gene expression have taken advantage of reverse transcription polymerase chain reaction's (RT-PCR) superior sensitivity and relative ease. The strategies used at the time were sufficient in measuring gene expression; however, they did present some inherent challenges. First, quantitation is relative to expression of an endogenous reference and therefore highly subjective. Second, data must be collected before entering the plateau phase of amplification. Therefore, the approach can be labor-intensive and is dependent on the judicious selection of cycling parameters to extrapolate kinetic data within the exponential (but before plateau) phase of amplification.
A number of methods have used synthetic RNA molecules as internal standards to control for differences in RT efficiencies in RT-PCR (7, 24) . This strategy provides the user with absolute quantitation; however, RNA standards require careful storage and are prone to degradation.
We therefore set out to design heterologous DNA competitors to the MDR1gene for competitive RT-PCR (CRT-PCR). Heterologous competitors share the same primer-binding sequences; however, they contain differing intervening sequences, so that once amplified, the sequences generate a larger-sized PCR product when compared to the endogenous target. This strategy was preferred, since homologous competitors can potentially realign with endogenous mRNA and form duplexes (11) . In the CRT-PCR approach, a known amount of DNA competitor is added with the cDNA preparation and amplified together. The advantage of this is that the competitor molecules contain identical primer sequences to the target. Therefore, the target sequence is in competition with the competitor for amplification. Because of the competitive nature of CRT-PCR, the amplification efficiencies of competitor and target sequences are identical.
At any number of cycles, the initial ratio of target ( t ) to competitor ( c ), ( Nti / Nci ) is equal to the ratio of amplified products ( Nt / Nc ) and the amount of amplified products ( At / Ac ), assuming the target and competitor fragments are amplified with similar efficiencies (25) . Therefore, it is not necessary to obtain data before the amplification reactions reach plateau. This is illustrated by Equation 1 (2, 17) :
Because the amplification efficiency between target and competitor molecules are identical, and the amount of competitor added to each reaction is known, we can determine the initial number of target (cDNA) molecules in the amplification reaction. As an internal reference, we constructed heterologous competitors for the H3.3gene. We chose this strategy because of its simplicity. The inclusion of an endogenous reference provides an excellent internal control for mRNA extraction and cDNA synthesis. The reliablility of this method is dependent on the efficiency of mRNA extraction and RT. Similarly, expression of the reference must be comparable between different samples.
In this study, we test whether heterologous DNA competitors can be used in CRT-PCR by examining the amplification kinetics of competitor/endogenous templates and validate the quantitative power of the assay in a number of pilot experiments using both cell lines and clinical samples. We have confirmed that heterologous DNA competitors demonstrate linear-phase kinetics with the endogenous transcripts. The approach to MDR1gene quantitation in this report provides some criteria for developing a standard strategy to quantitation, and it should be a useful tool.
MATERIALS AND METHODS

Maintenance of Cell Lines and Purification of B-Lymphocytes
The cell lines were grown in RPMI-1640 medium (Sigma, St. Louis, MO, USA) supplemented with 10% (vol/ vol) fetal bovine serum (FBS) in a humidified atmosphere of 5% CO 2 at 37°C. The multidrug resistant variant cell line, CEM-A7, was developed by stepwise selection of the CEM-CCRF T-cell lymphoblastic cell line in doxorubicin and maintained in medium containing the drug at 70 ng/mL. CEM-A7R was established from the CEM-A7 cell line in the absence of doxorubicin for 5 years (26) .
Peripheral blood (5 mL) was collected with permission from patients with B-cell chronic lymphocytic leukemia (B-CLL) and immediately diluted in equal volumes of sterile phosphatebuffered saline (PBS), Ficoll-Hypaque ® (Amersham Pharmacia Biotech, Uppsala, Sweden) overlaid and monocytes isolated after density centrifugation. Cells were then counted using a Coulter Counter (Dn model) and hemocytometer (Beckman Coulter, Fullerton, CA, USA), while cell viability was assessed using Trypan Blue staining. mRNA was purified no longer than 90 min after the collection of blood.
Oligonucleotide Primers
Primer sequences for H3.3 cDNA yielded a 215-bp product and correspond to exon 2 (282-301 nucleotides [nt] ) and exon 3 (476-495 nt). They are sense 5 ′ -CCACTGAACTTCTGATTC -GC-3 ′ and antisense 5 ′ -GCGTGCTA-GCTGGATGTCTT-3 ′ (6). Primers used to amplify human MDR1cDNA, yielded a 157-bp product and correspond to exon 21 (2596-2615 nt) and exon 22 (2733-2752 nt). They are sense 5 ′ -CCCATCATTGCAATAGC -AGG-3 ′ and antisense 5 ′ -GTTCAAA-CTTCTGCTCCTGA-3 ′ (18).
Construction of Heterologous DNA Competitors
Low-stringency PCR was used to construct the competitors for MDR1 and H3.3 amplification products. Briefly, low annealing temperatures were used to promote spurious amplification of the MDR1and H3.3primers on CEM-A7R genomic DNA and the pCAT ® -BASIC plasmid (Promega, Madison, WI, USA), respectively. A larger PCR product was excised from a NuSieve ® agarose gel (FMC BioProducts, Rockland, ME, USA), spin column-purified (Progen Ltd, Darra, QLD, Australia), cloned into the Sma I site of pGEM ® -7Z (3.1 kb) and used directly into CRT-PCR. The length of the normal MDR1target cDNA is 157 bp, and its competitor is 260 bp (3.36 kb), while the H3.3target cDNA is 215 bp, and its competitor is 320 bp (3.42 kb). To quantify the amount of H3.3and MDR1competitor, a known amount of native pGEM-7Z DNA was serially diluted to construct a standard curve. To these dilutions, H3.3 and MDR1com-petitor were added, and the products were resolved on agarose-ethidium, bromide-stained gel. The amount of signal intensity was determined by fluorescence using Gel Doc ™ 1000 Video Gel Documentation System with Molecular Analyst ® software Version 2.1 (Bio-Rad, Hercules, CA, USA). Similarly, the quantity of competitor was determined by measuring the absorbance at 260 nm with comparable results. To calculate the number of target molecules, we corrected for differences in fluorescence intensity and the length of the endogenous PCR product with that of the competitor. The level of cDNA in each reaction is equal to the minimum number of cells used in mRNA extraction. This is illustrated by Equation 2:
where: Nt equals the number of target molecules, Ncequals number of competitor molecules, Tsequals the target signal (relative fluorescence), Cs equals the competitor signal (relative fluorescence), Tl equals length of target, Cl equals length of competitor and cDNA is equivalent to the number of cells used in CRT-PCR.
mRNA Extraction
We used a poly(A) + mRNA Purification Kit, according to the manufac - (guanidinium thiocyanate/ N -lauroyl sarcosine) and centrifuged at 10 000 
cDNA Synthesis
The RT reaction included 100 ng of random primer, 0.5 mM of each dNTP and mRNA from the equivalent of 10 4 cells. The mixture was heated for 6 min at 70°C then chilled on ice. First-strand buffer was added at a final concentration 50 mM Tris-HCl (pH 8. Technologies) . This was mixed and split for H3.3and MDR1 amplification. Primers were added at 20 pmol per reaction. The cycling parameters consisted of an initial denaturation at 95°C for 1 min, followed by 32 cycles of 95°C for 60 s, 58°C for 60 s and 72°C for 60 s, with a final extension at 72°C for 10 min.
Twenty percent (approximately 15 µ L) of the H3.3and MDR1PCRs were removed, pooled and size-fractionated on 1.6% NuSieve gel stained with 0.6 µ g/mL ethidium bromide. Quantitative analyses were performed with the Gel Doc 1000 system with Molecular Analyst software Version 2.1.
RESULTS AND DISCUSSION
Heterologous Competitors Fulfill Linear Phase Kinetics
PCR quantitation can be performed by one of two common methods: (i) titration of the cDNA template that is amplified at a fixed number of cycles or (ii) by measuring the amplification kinetics at successive PCR cycles with a fixed amount of template (16) . These methods can be used to estimate the difference in initial amounts of target cDNA between samples. Two critical requirements must be addressed if quantitative results from PCR are to be meaningful. First, the amplification efficiency must be comparable for both the internal and target cDNA; second, quantitation must be performed before the reactions enter plateau phase.
To exemplify this, 100 ng of cDNA were titrated (1:2) to 3.1 ng from a patient with B-CLL and were used to amplify H3.3 and MDR1 following 34 PCR cycles ( Figure 1, Panel 1) . It was evident that differences in gene expression alter the amplification efficiencies and that comparisons between different samples would be difficult. One option before amplification was to dilute the internal reference so that its amplification curve was comparable with that of MDR1 . However, this would be time-consuming when analyzing multiple samples. Furthermore, quantitation by this method is subjective because it is dependent on exponential amplification of the endogenous reference. As a result, CRT-PCR was selected because quantitation is independent of reaction kinetics.
With the construction of DNA competitors, it was important to verify the linearity of amplification between the target ( t ) and competitor ( c ) molecules by comparing reaction kinetics. The initial target-to-competitor ratio ( Nti / Nci ) is equal to the number of amplified molecules ( Nt / Nc ) and to the amount of amplified molecules in fluorescence intensity ( At / Ac ), assuming target and competitor fragments are amplified with similar efficiencies (25) . To examine this, 10 3 amol of H3.3competitor and the equivalent of 30 ng of CEM-A7 cDNA were amplified up to 32 cycles ( Figure 1, Panel 2) . In this example, the amplification efficiencies for H3.3 were parallel when competitor and target were co-amplified. The ratios between the competitor-to-target molecules were equivalent at successive PCR cycles. The insert in Figure 1 , Panel 2 represents the amplification kinetics for the target transcript and H3.3 competitor when amplified independently. Regression analysis shows the significance in amplification curve was r 2 = 0.99 for both transcripts.
This strategy was also used to analyze the amplification kinetics for MDR1competitor and its target cDNA. When analyzed separately (Figure 1 , Panel 3, insert) or co-amplified ( Figure  1, Panel 3) , the competitor and cDNA slopes were similar, confirming these molecules have comparable reaction kinetics. The amplification curves were parallel and not influenced by template concentrations ( r 2 = 0.99). Furthermore, the target-to-competitor ratio remained steady when equimolar levels of standard were amplified with titrated cDNA (data not shown). All experiments were performed in triplicate, with less than 10% deviation for any single point.
In the next experiment, H3.3com-petitor was serially diluted (1:2) from 10 to 0.01 ng and amplified for 30 cycles ( Figure 1, Panel 4) . The ideal slope (thin line) represents the calculated curve for diluted H3.3competitor (Yaxis) vs. the log number of molecules (X-axis). The solid line illustrates the amplification curve for the H3.3com-petitor (Y-axis) vs. its log fluorescence signal (YY-axis). A linear relationship exists ( r = 0) at 32 cycles ( n ) between amplified product, Log A (fluorescence) and starting amount of template, Log Ao (ng), assuming E(amplification efficiency) is constant. This can be represented by Equation 3:
The insert in Figure 1 , Panel 4, displays the amplification kinetics for H3.3and MDR1 . Competitors were serially diluted 1:10 starting from 10 4 to 10 -1 amol and amplified for 32 cycles, since the H3.3and MDR1slopes almost overlap, these results indicate that similar levels of competitor were included in each PCR.
Measure of Assay Variability and CRT-PCR Performance
The reproducibility of competitive amplification was analyzed by calculating the relative and absolute gene levels in the drug-resistant CEM-A7 and HepG2 cell lines. For the CEM-A7 cells, we co-amplified 10 3 amol of competitor with serial dilutions (1:2) of cDNA to evaluate H3.3and MDR1 gene expression from low levels of template. The yield of amplified product was almost halved from 3.1 × 10 6 to 1.6 × 10 6 molecules for H3.3at 10 and 5 ng cDNA, respectively. Similarly, the number of MDR1molecules decreased from 3.21 ×10 6 to 1.68 ×10 6 molecules for 10 and 5 ng cDNA, respectively. As expected, the relative cDNA ratio for MDR1 / H3.3was 1.05 ±0.01 in both experiments. Secondly, we assessed intra-assay variability by comparing the MDR1 / H3.3 amplification in nine different experiments using variable CEM-A7 cDNA loads on different days. The MDR1 / H3.3ratio was comparable to previous experiments at 1.12 ± 0.08 ( n = 9) (data not shown).
In a separate experiment, we examined the resolution of the competitive PCR assay in quantifying target sequence. Figure 1 , Panel 5 illustrates the titration curves for H3.3and MDR1af -ter co-amplifying 5-25 ng mRNA with 10 3 amol of competitor. Following competitive amplification, the relative levels of H3.3and MDR1mRNA were quantified. A linear trend in H3.3and MDR1amplification was observed using comparative analyses ( r 2 = 0.99 for both curves). The MDR1 / H3.3ratio in HepG2 was calculated at 0.75 ± 0.07 for all reactions. Finally, the ability to discern subtle change in cDNA levels was also investigated. Serial dilutions (3:4) of HepG2 cDNA (over a range 25 -4.5 ng) and 10 3 amol of MDR1competitor were co-amplified in triplicate, following 34 cycles of amplification (Figure 1,  Panel 6 ). The change in cDNA titration was examined, and a close agreement could be measured between calculated and expected titration curves.
Absolute Quantitation of H3.3and MDR1
The housekeeping gene H3.3was used to control for differences in mRNA quality and cDNA yields. To study its expression, we analyzed the three CEM cell lines: (i) CEM-CCRF represent the drug-sensitive parental cell line ( MDR-); (ii)CEM-A7R is a moderately drug-resistant cell line derived from CEM-A7 and grown in the absence of doxorubicin; and (iii) CEM-A7 is a highly drug-resistant cell line and is a derivative of the CEM-CCRF cell line grown in doxorubicin.
Competitive PCR was performed with known amounts of H3.3competi -tor using serial dilutions (1:10), ranging from 10 4 to 10 -1 amol and cDNA equivalent to 10 3 cells in each PCR. By taking into account the number of cells used for mRNA extraction and efficiency of mRNA transcription, we calculated the minimum number of H3.3mole -cules per cell. Note that the calculations here are based on the number of target molecules per cell and therefore assume that the efficiency of mRNA extraction and cDNA conversion are 100%. The CRT-PCR assay provides sufficient sensitivity to quantify MDR1 mRNA; however, this technique can be limited by its inability to distinguish heterogenous cell populations typical in solid tumors. The ultimate success of CRT-PCR is dependent on the stringent use of controls and adherence of assay limits. The protocol discussed here is meant to provide some criteria for RT-PCR quantitation of MDR1gene expression and should complement rather than replace existing detection methods for Pgp. It is recommended that MDR1 mRNA studies include detection of the Pgp molecule and/or activity of the protein pump. In fact, Ludescher et al. suggested that the sensitivity of RT-PCR coupled with the selectivity of the Rh-123 assay were suitable candidates in clinical screening of MDR1 /Pgp in B-CLL (12) . In addition, a correlation between MDR1 detected by RT-PCR, protein expression detected by MRK-16 binding to Pgp and protein function measured by Rh-123 activity suggests that RT-PCR would complement other techniques (27) . The debate over the most suitable protocol(s) for MDR1 / Pgp is long standing (23), but there is no doubt that MDR1mRNA studies and assays measuring functional Pgp activity would prove more revealing than the use of a single assay.
In this study, we have demonstrated that competitve RT-PCR allows for rapid and accurate quantitation. Lowstringency PCR is a relatively simple technique for the construction of heterologous competitors and requires no mutagenic work (9,21) nor the use of composite primers (22) . The competitors are specific and allow estimates on the number of molecules per cell or molecules per ng mRNA. The endogenous reference allows the user to check for differences in mRNA extraction and cDNA synthesis. We found it inappropriate to use multiplex strategy (1) since significant interference was observed in the co-amplification reaction containing both MDR1 and H3.3ampli -fication primers (data not shown). Furthermore, the assay is sensitive and can reliably distinguish 25% change in the amount of target transcript with a high degree of confidence. This technique is sensitive enough for quantitation by nonradioactive means, does not require nested PCR to improve sensitivity (8) nor restriction digestion for signal detection (4). We plan to monitor MDR1 mRNA levels in patients with progressive B-CLL using this technique as a standard in mRNA quantitation.
